{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:35:08Z","timestamp":1793198108525,"version":"4.5.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100005743","name":"Universit\u00e0 Cattolica del Sacro Cuore","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005743","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40259-026-00781-1","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T10:19:48Z","timestamp":1776766788000},"page":"479-492","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Interleukin-23 Inhibitors in Inflammatory Bowel Disease"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0935-8853","authenticated-orcid":false,"given":"Pierluigi","family":"Puca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Parello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Colantuono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Tursi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loris Riccardo","family":"Lopetuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Scaldaferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gasbarrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Papa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"781_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25052789","volume":"25","author":"P Puca","year":"2024","unstructured":"Puca P, Capobianco I, Coppola G, Di Vincenzo F, Trapani V, Petito V, et al. Cellular and molecular determinants of biologic drugs resistance and therapeutic failure in inflammatory bowel disease. Int J Mol Sci. 2024;25:2789. https:\/\/doi.org\/10.3390\/ijms25052789.","journal-title":"Int J Mol Sci"},{"key":"781_CR2","doi-asserted-by":"publisher","unstructured":"Masi L, Ciuffini C, Petito V, Pisani LF, Lopetuso LR, Graziani C, et al. Innovative, complementary and alternative therapy in inflammatory bowel diseases: A broad 2020s update. Front Gastroenterol [Internet]. Frontiers; 2022 [cited 2025 Dec 14];1. https:\/\/doi.org\/10.3389\/fgstr.2022.1022530","DOI":"10.3389\/fgstr.2022.1022530"},{"key":"781_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13020305","volume":"13","author":"V Calvez","year":"2025","unstructured":"Calvez V, Puca P, Di Vincenzo F, Del Gaudio A, Bartocci B, Murgiano M, et al. Novel insights into the pathogenesis of inflammatory bowel diseases. Biomedicines. 2025;13:305. https:\/\/doi.org\/10.3390\/biomedicines13020305.","journal-title":"Biomedicines"},{"key":"781_CR4","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1016\/S0140-6736(24)01750-1","volume":"404","author":"V Jairath","year":"2024","unstructured":"Jairath V, Acosta Felquer ML, Cho RJ. IL-23 inhibition for chronic inflammatory disease. Lancet. 2024;404:1679\u201392. https:\/\/doi.org\/10.1016\/S0140-6736(24)01750-1.","journal-title":"Lancet"},{"key":"781_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf144","volume":"19","author":"CL Pugliano","year":"2025","unstructured":"Pugliano CL, Liang RF-H, Ruffa A, Iacucci M, Ghosh S. Practical considerations for the use of IL-23p19 inhibitors in inflammatory bowel disease: how to choose between them and why it matters? J Crohns Colitis. 2025;19:jjaf144. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf144.","journal-title":"J Crohns Colitis"},{"key":"781_CR6","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1084\/jem.20041257","volume":"201","author":"CL Langrish","year":"2005","unstructured":"Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005;201:233\u201340. https:\/\/doi.org\/10.1084\/jem.20041257.","journal-title":"J Exp Med"},{"key":"781_CR7","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/nature05505","volume":"445","author":"Y Zheng","year":"2007","unstructured":"Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, Wu J, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature. 2007;445:648\u201351. https:\/\/doi.org\/10.1038\/nature05505.","journal-title":"Nature"},{"key":"781_CR8","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1038\/s12276-025-01535-9","volume":"57","author":"E Park","year":"2025","unstructured":"Park E, Ciofani M. Th17 cell pathogenicity in autoimmune disease. Exp Mol Med. 2025;57:1913\u201327. https:\/\/doi.org\/10.1038\/s12276-025-01535-9.","journal-title":"Exp Mol Med"},{"key":"781_CR9","doi-asserted-by":"publisher","first-page":"ii54","DOI":"10.1093\/ecco-jcc\/jjac007","volume":"16","author":"R Atreya","year":"2022","unstructured":"Atreya R, Neurath MF. IL-23 blockade in Anti-TNF refractory IBD: from mechanisms to clinical reality. J Crohns Colitis. 2022;16:ii54-63. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac007.","journal-title":"J Crohns Colitis"},{"key":"781_CR10","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1136\/gutjnl-2017-315671","volume":"68","author":"H Schmitt","year":"2019","unstructured":"Schmitt H, Billmeier U, Dieterich W, Rath T, Sonnewald S, Reid S, et al. Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn\u2019s disease. Gut. 2019;68:814\u201328. https:\/\/doi.org\/10.1136\/gutjnl-2017-315671.","journal-title":"Gut"},{"key":"781_CR11","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1136\/gut.2006.116467","volume":"56","author":"S Kugathasan","year":"2007","unstructured":"Kugathasan S, Saubermann LJ, Smith L, Kou D, Itoh J, Binion DG, et al. Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease. Gut. 2007;56:1696\u2013705. https:\/\/doi.org\/10.1136\/gut.2006.116467.","journal-title":"Gut"},{"key":"781_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13010224","volume":"13","author":"J Fanizza","year":"2023","unstructured":"Fanizza J, D\u2019Amico F, Lusetti F, Fasulo E, Allocca M, Furfaro F, et al. The role of IL-23 inhibitors in Crohn\u2019s disease. J Clin Med. 2023;13:224. https:\/\/doi.org\/10.3390\/jcm13010224.","journal-title":"J Clin Med"},{"key":"781_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1053\/j.gastro.2024.05.036","volume":"168","author":"AR Bourgonje","year":"2025","unstructured":"Bourgonje AR, Ungaro RC, Mehandru S, Colombel J-F. Targeting the interleukin 23 pathway in inflammatory bowel disease. Gastroenterology. 2025;168:29-52.e3. https:\/\/doi.org\/10.1053\/j.gastro.2024.05.036.","journal-title":"Gastroenterology"},{"key":"781_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13706","volume":"17","author":"Y Pang","year":"2024","unstructured":"Pang Y, D\u2019Cunha R, Winzenborg I, Veldman G, Pivorunas V, Wallace K. Risankizumab: mechanism of action, clinical and translational science. Clin Transl Sci. 2024;17:e13706. https:\/\/doi.org\/10.1111\/cts.13706.","journal-title":"Clin Transl Sci"},{"key":"781_CR15","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1186\/s40001-025-03346-0","volume":"30","author":"Y Yuan","year":"2025","unstructured":"Yuan Y, Li L, Yang L, Zheng J, Gao G, Tan T, et al. Single-cell RNA sequencing and in vitro validation reveal Risankizumab induces anti-inflammatory macrophage polarization in psoriasis. Eur J Med Res. 2025;30:1114. https:\/\/doi.org\/10.1186\/s40001-025-03346-0.","journal-title":"Eur J Med Res"},{"key":"781_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14030654","volume":"14","author":"K Rodr\u00edguez-Fern\u00e1ndez","year":"2022","unstructured":"Rodr\u00edguez-Fern\u00e1ndez K, Mangas-Sanju\u00e1n V, Merino-Sanju\u00e1n M, Martorell-Calatayud A, Mateu-Puchades A, Climente-Mart\u00ed M, et al. Impact of pharmacokinetic and pharmacodynamic properties of monoclonal antibodies in the management of psoriasis. Pharmaceutics. 2022;14:654. https:\/\/doi.org\/10.3390\/pharmaceutics14030654.","journal-title":"Pharmaceutics"},{"key":"781_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1532852","volume":"16","author":"KL Sachen","year":"2025","unstructured":"Sachen KL, Hammaker D, Sarabia I, Stoveken B, Hartman J, Leppard KL, et al. Guselkumab binding to CD64+ IL-23-producing myeloid cells enhances potency for neutralizing IL-23 signaling. Front Immunol. 2025;16:1532852. https:\/\/doi.org\/10.3389\/fimmu.2025.1532852.","journal-title":"Front Immunol"},{"key":"781_CR18","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1007\/s40262-023-01281-z","volume":"62","author":"L Chua","year":"2023","unstructured":"Chua L, Friedrich S, Zhang XC. Mirikizumab pharmacokinetics in patients with moderately to severely active ulcerative colitis: results from Phase III LUCENT studies. Clin Pharmacokinet. 2023;62:1479\u201391. https:\/\/doi.org\/10.1007\/s40262-023-01281-z.","journal-title":"Clin Pharmacokinet"},{"key":"781_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00958","volume":"9","author":"G-M Lilienthal","year":"2018","unstructured":"Lilienthal G-M, Rahm\u00f6ller J, Petry J, Bartsch YC, Leliavski A, Ehlers M. Potential of murine IgG1 and human IgG4 to inhibit the classical complement and Fc\u03b3 receptor activation pathways. Front Immunol. 2018;9:958. https:\/\/doi.org\/10.3389\/fimmu.2018.00958.","journal-title":"Front Immunol"},{"key":"781_CR20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2406192121","volume":"121","author":"N Frischauf","year":"2024","unstructured":"Frischauf N, Strasser J, Borg EGF, Labrijn AF, Beurskens FJ, Preiner J. Complement activation by IgG subclasses is governed by their ability to oligomerize upon antigen binding. Proc Natl Acad Sci U S A. 2024;121:e2406192121. https:\/\/doi.org\/10.1073\/pnas.2406192121.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"781_CR21","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1001\/jama.2024.12414","volume":"332","author":"E Louis","year":"2024","unstructured":"Louis E, Schreiber S, Panaccione R, Bossuyt P, Biedermann L, Colombel J-F, et al. Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials. JAMA. 2024;332:881\u201397. https:\/\/doi.org\/10.1001\/jama.2024.12414.","journal-title":"JAMA"},{"key":"781_CR22","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","volume":"388","author":"G D\u2019Haens","year":"2023","unstructured":"D\u2019Haens G, Dubinsky M, Kobayashi T, Irving PM, Howaldt S, Pokrotnieks J, et al. Mirikizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2023;388:2444\u201355. https:\/\/doi.org\/10.1056\/NEJMoa2207940.","journal-title":"N Engl J Med"},{"key":"781_CR23","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1093\/ibd\/izae024","volume":"30","author":"BE Sands","year":"2024","unstructured":"Sands BE, D\u2019Haens G, Clemow DB, Irving PM, Johns JT, Hunter Gibble T, et al. Two-year efficacy and safety of Mirikizumab following 104 weeks of continuous treatment for ulcerative colitis: results from the LUCENT-3 open-label extension study. Inflamm Bowel Dis. 2024;30:2245\u201358. https:\/\/doi.org\/10.1093\/ibd\/izae024.","journal-title":"Inflamm Bowel Dis"},{"key":"781_CR24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0140-6736(24)01927-5","volume":"405","author":"DT Rubin","year":"2025","unstructured":"Rubin DT, Allegretti JR, Pan\u00e9s J, Shipitofsky N, Yarandi SS, Huang K-HG, et al. Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies. Lancet. 2025;405:33\u201349. https:\/\/doi.org\/10.1016\/S0140-6736(24)01927-5.","journal-title":"Lancet"},{"key":"781_CR25","doi-asserted-by":"publisher","unstructured":"Lichtenstein GR, Allegretti JR, Rubin DT, Feagan BG, Bressler B, Pan\u00e9s J, et al. Su1856: Efficacy and safety of GUSELKUMAB for ulcerative colitis through week 92 of the quasar long-term extension study. Gastroenterology. Elsevier; 2025;169:S. https:\/\/doi.org\/10.1016\/S0016-5085(25)02917-8","DOI":"10.1016\/S0016-5085(25)02917-8"},{"key":"781_CR26","doi-asserted-by":"publisher","first-page":"i19","DOI":"10.1093\/ecco-jcc\/jjae190.0010","volume":"19","author":"L Peyrin-Biroulet","year":"2025","unstructured":"Peyrin-Biroulet L, Allegretti JR, Danese S, Germinaro M, Baker T, Alvarez Y, et al. OP10 efficacy and safety of subcutaneous guselkumab induction therapy in patients with Ulcerative Colitis: results through week 12 from the phase 3 ASTRO study. J Crohns Colitis. 2025;19:i19-20. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae190.0010.","journal-title":"J Crohns Colitis"},{"key":"781_CR27","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S2468-1253(25)00322-X","volume":"11","author":"M Long","year":"2026","unstructured":"Long M, Allegretti JR, Danese S, Germinaro M, Baker T, Alvarez Y, et al. Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2026;11:284\u201398. https:\/\/doi.org\/10.1016\/S2468-1253(25)00322-X.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"781_CR28","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/S0140-6736(22)00467-6","volume":"399","author":"G D\u2019Haens","year":"2022","unstructured":"D\u2019Haens G, Panaccione R, Baert F, Bossuyt P, Colombel J-F, Danese S, et al. Risankizumab as induction therapy for Crohn\u2019s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet Lond Engl. 2022;399:2015\u201330. https:\/\/doi.org\/10.1016\/S0140-6736(22)00467-6.","journal-title":"Lancet Lond Engl."},{"key":"781_CR29","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(22)00466-4","volume":"399","author":"M Ferrante","year":"2022","unstructured":"Ferrante M, Panaccione R, Baert F, Bossuyt P, Colombel J-F, Danese S, et al. Risankizumab as maintenance therapy for moderately to severely active Crohn\u2019s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. The Lancet. 2022;399:2031\u201346. https:\/\/doi.org\/10.1016\/S0140-6736(22)00466-4.","journal-title":"The Lancet"},{"key":"781_CR30","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1016\/S0140-6736(24)01762-8","volume":"404","author":"M Ferrante","year":"2024","unstructured":"Ferrante M, D\u2019Haens G, Jairath V, Danese S, Chen M, Ghosh S, et al. Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn\u2019s disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study. Lancet Lond Engl. 2024;404:2423\u201336. https:\/\/doi.org\/10.1016\/S0140-6736(24)01762-8.","journal-title":"Lancet Lond Engl."},{"key":"781_CR31","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1053\/j.gastro.2025.02.033","volume":"169","author":"A Hart","year":"2025","unstructured":"Hart A, Panaccione R, Steinwurz F, Danese S, Hisamatsu T, Cao Q, et al. Efficacy and safety of guselkumab subcutaneous induction and maintenance in participants with moderately to severely active Crohn\u2019s Disease: results from the phase 3 GRAVITI study. Gastroenterology. 2025;169:308\u201325. https:\/\/doi.org\/10.1053\/j.gastro.2025.02.033.","journal-title":"Gastroenterology"},{"key":"781_CR32","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(25)00681-6","volume":"406","author":"R Panaccione","year":"2025","unstructured":"Panaccione R, Feagan BG, Afzali A, Rubin DT, Reinisch W, Pan\u00e9s J, et al. Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn\u2019s disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials. The Lancet. 2025;406:358\u201375. https:\/\/doi.org\/10.1016\/S0140-6736(25)00681-6.","journal-title":"The Lancet"},{"key":"781_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1490667","volume":"16","author":"S Wang","year":"2025","unstructured":"Wang S, Sun H, Wang Q, Xiao H. Efficacy and safety of IL-23 p19 inhibitors in the treatment for inflammatory bowel disease: a systematic review and meta-analysis. Front Pharmacol. 2025;16:1490667. https:\/\/doi.org\/10.3389\/fphar.2025.1490667.","journal-title":"Front Pharmacol"},{"key":"781_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2026.01.049","author":"BE Sands","year":"2026","unstructured":"Sands BE, Barnes EL, D\u2019Haens G, Hisamatsu T, Regueiro M, Kelly CR, et al. Mirikizumab long-term efficacy and safety in patients with crohn\u2019s disease: results from the VIVID-2 open-label extension trial. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2026. https:\/\/doi.org\/10.1016\/j.cgh.2026.01.049.","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"781_CR35","doi-asserted-by":"crossref","unstructured":"DOP104 Efficacy and safety of guselkumab for ulcerative colitis through week 140 of the QUASAR long-term extension study | Journal of Crohn\u2019s and Colitis | Oxford Academic [Internet]. [cited 2026 Mar 23]. https:\/\/academic.oup.com\/ecco-jcc\/article\/20\/Supplement_1\/jjaf231.141\/8432651?login=false. Accessed 23 Mar 2026","DOI":"10.1093\/ecco-jcc\/jjaf231.141"},{"key":"781_CR36","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1001\/jama.2023.4855","volume":"329","author":"RC Sheldrick","year":"2023","unstructured":"Sheldrick RC. Randomized trials vs real-world evidence: how can both inform decision-making? JAMA. 2023;329:1352\u20133. https:\/\/doi.org\/10.1001\/jama.2023.4855.","journal-title":"JAMA"},{"key":"781_CR37","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2147\/PTT.S533005","volume":"15","author":"E Mortato","year":"2025","unstructured":"Mortato E, Talamonti M, Marcelli L, Megna M, Raimondo A, Caldarola G, et al. Long-term real-world effectiveness and drug survival of guselkumab in patients with psoriasis: a 5-year retrospective study. Psoriasis Targets Ther. 2025;15:455\u201369. https:\/\/doi.org\/10.2147\/PTT.S533005.","journal-title":"Psoriasis Targets Ther."},{"key":"781_CR38","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2147\/BTT.S530354","volume":"19","author":"F D\u2019Amico","year":"2025","unstructured":"D\u2019Amico F, Bencardino S, Magro F, Dignass A, Guti\u00e9rrez Casbas A, Verstockt B, et al. Positioning Guselkumab in the treatment algorithm of patients with Crohn\u2019s disease. Biol Targets Ther. 2025;19:351\u201363. https:\/\/doi.org\/10.2147\/BTT.S530354.","journal-title":"Biol Targets Ther."},{"key":"781_CR39","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad212.1103","volume":"18","author":"DG Ribaldone","year":"2024","unstructured":"Ribaldone DG, Palumbo A, Cariti C, Susca S, Merli M, Saracco GM, et al. P973 Real-world data on the effectiveness on IBD of anti-IL23 drugs prescribed for psoriasis indication. J Crohns Colitis. 2024;18:i1755. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad212.1103.","journal-title":"J Crohns Colitis"},{"key":"781_CR40","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1111\/apt.70140","volume":"61","author":"Y Takagi","year":"2025","unstructured":"Takagi Y, Sato T, Nishiguchi T, Nogami A, Igeta M, Yagi S, et al. Real-world effectiveness and safety of Mirikizumab induction therapy in patients with ulcerative colitis: a multicentre retrospective observational study. Aliment Pharmacol Ther. 2025;61:1923\u201334. https:\/\/doi.org\/10.1111\/apt.70140.","journal-title":"Aliment Pharmacol Ther"},{"key":"781_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0334897","volume":"20","author":"A Kubesch","year":"2025","unstructured":"Kubesch A, Lande R, Leutg\u00f6b A, Farrag K, Dahmer I, Stratmann-Vollrath K, et al. Sequencing therapy for optimal response in Mirikizumab (STORM)-study: a tertiary referral center study on patients with therapy-refractory ulcerative colitis. PLoS ONE. 2025;20:e0334897. https:\/\/doi.org\/10.1371\/journal.pone.0334897.","journal-title":"PLoS ONE"},{"key":"781_CR42","doi-asserted-by":"publisher","DOI":"10.1177\/17562848251392074","volume":"18","author":"A Levartovsky","year":"2025","unstructured":"Levartovsky A, Luk\u00e1\u0161 M, Abitbol CM, Vlkov\u00e1 K, Ben-Horin S, Luk\u00e1\u0161 M, et al. Mirikizumab in ulcerative colitis: real-world evidence from an international two-center retrospective cohort study. Ther Adv Gastroenterol. 2025;18:17562848251392074. https:\/\/doi.org\/10.1177\/17562848251392074.","journal-title":"Ther Adv Gastroenterol"},{"key":"781_CR43","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1007\/s10620-025-08950-y","volume":"70","author":"J St-Pierre","year":"2025","unstructured":"St-Pierre J, Choi D, Fear E, Choi NK, Mathew AJ, Cohen RD, et al. Mirikizumab in the treatment of ulcerative colitis: initial real-world data in a population from a large tertiary center. Dig Dis Sci. 2025;70:1864\u201372. https:\/\/doi.org\/10.1007\/s10620-025-08950-y.","journal-title":"Dig Dis Sci"},{"key":"781_CR44","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1093\/ibd\/izad315","volume":"30","author":"D Alsoud","year":"2024","unstructured":"Alsoud D, Sabino J, Franchimont D, Cremer A, Busschaert J, D\u2019Heygere F, et al. Real-world effectiveness and safety of Risankizumab in patients with moderate to severe multirefractory Crohn\u2019s Disease: a Belgian multicentric cohort study. Inflamm Bowel Dis. 2024;30:2289\u201396. https:\/\/doi.org\/10.1093\/ibd\/izad315.","journal-title":"Inflamm Bowel Dis"},{"key":"781_CR45","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1093\/crocol\/otaf062","volume":"7","author":"MN Alzaabi","year":"2025","unstructured":"Alzaabi MN, Swaid TK, Ahmed HA, Alahmad MA, Omar NM, Chitra Kumar KK, et al. Real-world effectiveness of risankizumab in Crohn\u2019s disease: outcome data for an IL-23 inhibitor from the middle east. Crohns Colitis. 2025;7:62. https:\/\/doi.org\/10.1093\/crocol\/otaf062.","journal-title":"Crohns Colitis"},{"key":"781_CR46","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1016\/j.cgh.2024.04.016","volume":"22","author":"M Fumery","year":"2024","unstructured":"Fumery M, Caron B, H\u00e9buterne X, Altwegg R, Roblin X, Stefanescu C, et al. Long-term outcome of Risankizumab in Crohn\u2019s Disease: a real-world GETAID study. Clin Gastroenterol Hepatol. 2024;22:2451-2458.e1. https:\/\/doi.org\/10.1016\/j.cgh.2024.04.016.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"781_CR47","doi-asserted-by":"publisher","DOI":"10.1177\/17562848251375844","volume":"18","author":"C-S Chung","year":"2025","unstructured":"Chung C-S, Chang C-H, Kuo C-J, Chou J-W, Huang T-Y, Hsu W-H, et al. Efficacy and safety of Risankizumab for moderate-to-severe Crohn\u2019s Disease: first Asian real-world data (STAR trial). Ther Adv Gastroenterol. 2025;18:17562848251375844. https:\/\/doi.org\/10.1177\/17562848251375844.","journal-title":"Ther Adv Gastroenterol"},{"key":"781_CR48","doi-asserted-by":"publisher","unstructured":"Scaldaferri F, Di Vincenzo F, Aloi M, Ascolani M, Balestrieri P, Bertani L, et al. Multicenter real-world outcomes of risankizumab in Crohn\u2019s disease: the RESOLVE IG-IBD study. Am J Gastroenterol. 2026; https:\/\/doi.org\/10.14309\/ajg.0000000000003969","DOI":"10.14309\/ajg.0000000000003969"},{"issue":"25","key":"781_CR49","doi-asserted-by":"publisher","first-page":"00935","DOI":"10.1016\/j.cgh.2025.10.026","volume":"S1542\u20133565","author":"M Kayal","year":"2025","unstructured":"Kayal M, Jimenez D, Huang J, Spencer EA. Comparable 12-week and superior 24-week remission with Risankizumab vs Ustekinumab for Crohn\u2019s-like disease of the pouch. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2025;S1542\u20133565(25):00935\u20138. https:\/\/doi.org\/10.1016\/j.cgh.2025.10.026.","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc."},{"key":"781_CR50","doi-asserted-by":"publisher","DOI":"10.14309\/crj.0000000000001476","volume":"11","author":"N Lan","year":"2024","unstructured":"Lan N, Shen B. Efficacy and safety of Risankizumab in the treatment of Crohn\u2019s Disease of the pouch. ACG Case Rep J. 2024;11:e01476. https:\/\/doi.org\/10.14309\/crj.0000000000001476.","journal-title":"ACG Case Rep J"},{"key":"781_CR51","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1093\/ibd\/izae164","volume":"31","author":"M Kayal","year":"2024","unstructured":"Kayal M, Spencer EA, Smyth M, Raffals L, Qazi T, Deepak P, et al. Risankizumab is effective for the management of Crohn\u2019s disease of the pouch. Inflamm Bowel Dis. 2024;31:878\u201381. https:\/\/doi.org\/10.1093\/ibd\/izae164.","journal-title":"Inflamm Bowel Dis"},{"key":"781_CR52","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14931","volume":"34","author":"R Russo","year":"2021","unstructured":"Russo R, Gasparini G, Cozzani E, Burlando M, Parodi A. Considerations on inhibition of IL\u201023 in psoriatic women of childbearing potential. Dermatol Ther. 2021;34:e14931. https:\/\/doi.org\/10.1111\/dth.14931.","journal-title":"Dermatol Ther"},{"key":"781_CR53","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s40259-022-00564-4","volume":"37","author":"A Dernoncourt","year":"2023","unstructured":"Dernoncourt A, Liabeuf S, Bennis Y, Masmoudi K, Bodeau S, Laville S, et al. Fetal and Neonatal Adverse Drug Reactions Associated with Biologics Taken During Pregnancy by Women with Autoimmune Diseases: Insights from an Analysis of the World Health Organization Pharmacovigilance Database (VigiBase\u00ae). BioDrugs Clin Immunother Biopharm Gene Ther. 2023;37:73\u201387. https:\/\/doi.org\/10.1007\/s40259-022-00564-4.","journal-title":"BioDrugs Clin Immunother Biopharm Gene Ther."},{"key":"781_CR54","doi-asserted-by":"publisher","unstructured":"Murgiano M, Del Gaudio A, Puca P, Parello S, Calvez V, Buongiorno S, et al. Mirikizumab effectiveness in a pregnant woman with acute severe ulcerative colitis: a case report. Minerva Gastroenterol. 2025;71:370\u20135. https:\/\/doi.org\/10.23736\/S2724-5985.25.04010-0","DOI":"10.23736\/S2724-5985.25.04010-0"},{"key":"781_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14186472","volume":"14","author":"I-A Koumprentziotis","year":"2025","unstructured":"Koumprentziotis I-A, Stefanaki I, Routsi E, Vavouli C, Panagakis P, Papoutsaki M, et al. Long-term outcomes of Guselkumab and Risankizumab for the management of moderate-to-severe psoriasis in the elderly: results from a real-world retrospective study. J Clin Med. 2025;14:6472. https:\/\/doi.org\/10.3390\/jcm14186472.","journal-title":"J Clin Med"},{"key":"781_CR56","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1111\/jdv.19328","volume":"37","author":"K Kridin","year":"2023","unstructured":"Kridin K, Zirpel H, Mruwat N, Ludwig RJ, Thaci D. Evaluating the risk of infections under interleukin 23 and interleukin 17 inhibitors relative to tumour necrosis factor inhibitors - A population-based study. J Eur Acad Dermatol Venereol. 2023;37:2319\u201326. https:\/\/doi.org\/10.1111\/jdv.19328.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"781_CR57","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.abd.2023.08.004","volume":"99","author":"R Romiti","year":"2024","unstructured":"Romiti R, Hirayama ALdaS, Porro AM, Gon\u00e7alves HdeS, Miot LDB, Dur\u00e3es SMB, et al. Infections in the era of immunobiologicals. An Bras Dermatol. 2024;99:167\u201380. https:\/\/doi.org\/10.1016\/j.abd.2023.08.004.","journal-title":"An Bras Dermatol"},{"key":"781_CR58","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2025.2595874","volume":"57","author":"M Kaneko","year":"2025","unstructured":"Kaneko M, Sakuraba A. Efficacy and safety of IL-23p19 and IL-12\/23p40 inhibitors in moderate-to-severe Crohn\u2019s disease: a systematic review and network meta-analysis. Ann Med. 2025;57:2595874. https:\/\/doi.org\/10.1080\/07853890.2025.2595874.","journal-title":"Ann Med"},{"issue":"25","key":"781_CR59","doi-asserted-by":"publisher","first-page":"00196","DOI":"10.1016\/S2468-1253(25)00196-7","volume":"S2468\u20131253","author":"JL Kaplan","year":"2025","unstructured":"Kaplan JL, Bousvaros A, Turner D, Dubinsky M, Larkin A, Johns J, et al. Efficacy and safety of mirikizumab in paediatric participants with moderately-to-severely active ulcerative colitis (SHINE-1): a multicentre, open-label, non-randomised phase 2 trial. Lancet Gastroenterol Hepatol. 2025;S2468\u20131253(25):00196\u20137. https:\/\/doi.org\/10.1016\/S2468-1253(25)00196-7.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"781_CR60","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaf291","author":"K Jimbo","year":"2025","unstructured":"Jimbo K, Arai N, Suzuki M, Suzuki E, Hibio M, Nagata M, et al. Real-world effectiveness of and optimization strategies for Mirikizumab in pediatric ulcerative colitis: A prospective, observational study. Inflamm Bowel Dis. 2025. https:\/\/doi.org\/10.1093\/ibd\/izaf291.","journal-title":"Inflamm Bowel Dis"},{"key":"781_CR61","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae190.1336","volume":"19","author":"A Alsarhan","year":"2025","unstructured":"Alsarhan A, Tzivinikos C. P1162 novel use of Risankizumab in children with refractory Crohn\u2019s disease\u202f: case series. J Crohns Colitis. 2025;19:i2120. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae190.1336.","journal-title":"J Crohns Colitis"},{"key":"781_CR62","doi-asserted-by":"publisher","first-page":"ii64","DOI":"10.1093\/ecco-jcc\/jjab185","volume":"16","author":"TL Parigi","year":"2022","unstructured":"Parigi TL, Iacucci M, Ghosh S. Blockade of IL-23: What is in the pipeline? J Crohns Colitis. 2022;16:ii64-72. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab185.","journal-title":"J Crohns Colitis"},{"key":"781_CR63","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1007\/s12325-025-03213-8","volume":"42","author":"L Stein Gold","year":"2025","unstructured":"Stein Gold L, Eyerich K, Merola JF, Torres J, Coates LC, Allegretti JR. Oral peptide therapeutics as an emerging treatment modality in immune-mediated inflammatory diseases: a narrative review. Adv Ther. 2025;42:3158\u201372. https:\/\/doi.org\/10.1007\/s12325-025-03213-8.","journal-title":"Adv Ther"},{"key":"781_CR64","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf231.029","volume":"20","author":"E Louis","year":"2026","unstructured":"Louis E, Jairath V, Siegmund B, Kannan AK, Zeeman M, Hart A, et al. OP29 Icotrokinra, the first targeted oral peptide that selectively blocks the interleukin-23 receptor, reduces systemic and tissue inflammatory burden in ulcerative colitis: Results from the ANTHEM-UC study. J Crohns Colitis. 2026;20:jjaf231.029. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf231.029.","journal-title":"J Crohns Colitis"},{"key":"781_CR65","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/S2468-1253(25)00296-1","volume":"11","author":"V Jairath","year":"2026","unstructured":"Jairath V, Danese S, D\u2019Haens GR, Feagan BG, Peyrin-Biroulet L, Sands BE, et al. Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial. Lancet Gastroenterol Hepatol. 2026;11:34\u201345. https:\/\/doi.org\/10.1016\/S2468-1253(25)00296-1.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"781_CR66","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf231.155","author":"A Sapone","year":"2026","unstructured":"Sapone A, Neelakantan S, Banfield C, Hung K, Pradhan V, Zhao Y, et al. DOP118 a phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the p40xTL1A bispecific antibody PF-07261271 in healthy participants. J Crohns Colitis. 2026. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf231.155.","journal-title":"J Crohns Colitis"},{"key":"781_CR67","unstructured":"Innovent Biologics (Suzhou) Co. Ltd. A Phase I Randomized, Double-Blind, Placebo-Controlled, Single Subcutaneous or Intravenous Ascending Dose Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IBI112 in Healthy Subjects [Internet]. clinicaltrials.gov; 2022 Sept. Report No.: NCT04511624. https:\/\/clinicaltrials.gov\/study\/NCT04511624. Accessed 6 Jan 2026"},{"key":"781_CR68","unstructured":"Innovent Biologics (Suzhou) Co. Ltd. A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of IBI112 in Patients With Moderate to Severe Active Ulcerative Colitis [Internet]. clinicaltrials.gov; 2025 Nov. Report No.: NCT05377580. https:\/\/clinicaltrials.gov\/study\/NCT05377580. Accessed 6 Jan 2026"},{"key":"781_CR69","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s40259-019-00400-2","volume":"34","author":"Q Zhao","year":"2020","unstructured":"Zhao Q. Bispecific antibodies for autoimmune and inflammatory diseases: Clinical progress to date. BioDrugs. 2020;34:111\u20139. https:\/\/doi.org\/10.1007\/s40259-019-00400-2.","journal-title":"BioDrugs"},{"key":"781_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14051536","volume":"14","author":"AM Caballero Mateos","year":"2025","unstructured":"Caballero Mateos AM, Ca\u00f1adas de la Fuente GA, Gros B. Paradigm shift in inflammatory bowel disease management: Precision medicine, artificial intelligence, and emerging therapies. J Clin Med. 2025;14:1536. https:\/\/doi.org\/10.3390\/jcm14051536.","journal-title":"J Clin Med"},{"key":"781_CR71","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1002\/cpt.3235","volume":"115","author":"J Shao","year":"2024","unstructured":"Shao J, Vetter M, Vermeulen A, Feagan BG, Sands BE, Pan\u00e9s J, et al. Combination therapy with Guselkumab and Golimumab in patients with moderately to severely active ulcerative colitis: Pharmacokinetics, immunogenicity and drug-drug interactions. Clin Pharmacol Ther. 2024;115:1418\u201327. https:\/\/doi.org\/10.1002\/cpt.3235.","journal-title":"Clin Pharmacol Ther"},{"key":"781_CR72","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S2468-1253(22)00427-7","volume":"8","author":"BG Feagan","year":"2023","unstructured":"Feagan BG, Sands BE, Sandborn WJ, Germinaro M, Vetter M, Shao J, et al. Guselkumab plus Golimumab combination therapy versus Guselkumab or Golimumab monotherapy in patients with ulcerative colitis (VEGA): A randomised, double-blind, controlled, phase 2, proof-of-concept trial. Lancet Gastroenterol Hepatol. 2023;8:307\u201320. https:\/\/doi.org\/10.1016\/S2468-1253(22)00427-7.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"781_CR73","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13112667","volume":"13","author":"A Laffusa","year":"2025","unstructured":"Laffusa A, Burti C, Vigan\u00f2 C, Poggi F, Grieco L, Occhipinti V, et al. Inflammatory bowel disease: Understanding therapeutic effects of distinct molecular inhibitors as the key to current and future advanced therapeutic strategies. Biomedicines. 2025;13:2667. https:\/\/doi.org\/10.3390\/biomedicines13112667.","journal-title":"Biomedicines"},{"key":"781_CR74","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s40265-025-02183-z","volume":"85","author":"OM Nardone","year":"2025","unstructured":"Nardone OM, Vuyyuru SK, Yuan Y, Hanzel J, Jairath V. Differentiating IL-23 inhibitors in Crohn\u2019s disease. Drugs. 2025;85:725\u201340. https:\/\/doi.org\/10.1007\/s40265-025-02183-z.","journal-title":"Drugs"},{"key":"781_CR75","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1053\/j.gastro.2024.07.046","volume":"167","author":"AN Ananthakrishnan","year":"2024","unstructured":"Ananthakrishnan AN, Murad MH, Scott FI, Agrawal M, Haydek JP, Limketkai BN, et al. Comparative efficacy of advanced therapies for management of moderate-to-severe ulcerative colitis: 2024 American Gastroenterological Association evidence synthesis. Gastroenterology. 2024;167:1460\u201382. https:\/\/doi.org\/10.1053\/j.gastro.2024.07.046.","journal-title":"Gastroenterology"},{"key":"781_CR76","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","volume":"16","author":"T Raine","year":"2022","unstructured":"Raine T, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, et al. ECCO guidelines on therapeutics in ulcerative colitis: Medical treatment. J Crohns Colitis. 2022;16:2\u201317. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab178.","journal-title":"J Crohns Colitis"},{"key":"781_CR77","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1053\/j.gastro.2024.10.001","volume":"167","author":"S Singh","year":"2024","unstructured":"Singh S, Loftus EV, Limketkai BN, Haydek JP, Agrawal M, Scott FI, et al. AGA living clinical practice guideline on pharmacological management of moderate-to-severe ulcerative colitis. Gastroenterology. 2024;167:1307\u201343. https:\/\/doi.org\/10.1053\/j.gastro.2024.10.001.","journal-title":"Gastroenterology"},{"key":"781_CR78","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.1136\/gutjnl-2024-334395","volume":"74","author":"GW Moran","year":"2025","unstructured":"Moran GW, Gordon M, Sinopolou V, Radford SJ, Darie A-M, Vuyyuru SK, et al. British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025. Gut. 2025;74:s1-101. https:\/\/doi.org\/10.1136\/gutjnl-2024-334395.","journal-title":"Gut"},{"key":"781_CR79","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abq4473","volume":"14","author":"MF Neurath","year":"2022","unstructured":"Neurath MF. Targeting cytokines in inflammatory bowel disease. Sci Transl Med. 2022;14:eabq4473. https:\/\/doi.org\/10.1126\/scitranslmed.abq4473.","journal-title":"Sci Transl Med"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00781-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-026-00781-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00781-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T11:46:48Z","timestamp":1779796008000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-026-00781-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":79,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["781"],"URL":"https:\/\/doi.org\/10.1007\/s40259-026-00781-1","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"8 April 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No conflict of interests to declare from any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All authors contributed to the study conception and design. Literature search and manuscript preparation were performed by PP, GC, and SP, and SC, LRL, and FS reviewed the manuscript. AP, AG, and AT supervised the entire work. All authors read and approved the final manuscript and provided their consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}